Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa

Overview of attention for article published in Orphanet Journal of Rare Diseases, May 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#23 of 2,673)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 24 news stories from 15 outlets.

NEWTON, Mass. and GENEVA, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc.

Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation Key ACER-001…

GlobeNewswire 2021-10-26 Key ACER-001 formulation composition of matter patent strengthens proprietary position in U.S.

NEWTON, Mass. and GENEVA, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 20 additional news stories.